anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Background: Neck pain effects a significant number of individuals and is commonly treated with chiropractic cervical manipulation. The temporary increases in neck pain following cervical manipulation may contribute to a lack of compliance with prescribed therapy that following this therapy which in turn commonly contributes to protracted symptoms. Topical menthol has previously been shown to decrease pain shortly following application. The purpose of this study was to determine if patients with mechanical neck pain who received topical menthol gel applied to their neck prior to cervical manipulation would have less pain and increased neck range of motion following cervical manipulation than patients who did not receive menthol.

Methods: Patients, mean ages 35 years old, with non-radicular mechanical neck pain were randomly assigned to a control (n=31) or a treatment (n=29) group. Five minutes before cervical manipulation, controls received a placebo gel applied to their neck while the treatment group received a menthol containing gel (Biofreeze®) applied to their neck. Participants rated their neck pain on a 10-point scale prior to gel application (Pre) and at one minute (T1), 10 minutes (T2), 20 minutes (T3), and 30 minutes (T4) post cervical manipulation. Six measures of neck range of motion were assessed prior to topical applications of gel and at T1 and T4. ANCOVA repeated measures were performed to compare pain ratings and neck range of motion following manipulation while controlling for Pre measures.
Nanoparticulate compositions comprising a corticosteroid and a leukotriene receptor antagonist are described. The compositions are useful in the prophylaxis and chronic treatment of asthma in adults and pediatric patients and for the relief of allergic conjunctivitis, symptoms of seasonal allergic rhinitis in adults and pediatric patients. Combining a leukotriene receptor antagonist with a corticosteroid in a particle size ranges of less than 2000 nm in a single formulation results in improved efficacy. In addition, patient compliance is enhanced since only one dosage form is needed. Furthermore, local administration of the leukotriene receptor antagonist results in less liver toxicity since the liver will be exposed to lower amounts of drug than happens following oral administration. The drug compositions according to the invention can be formulated into inhalation, nasal, or ocular formulations.
BACKGROUND: To improve diagnostic precision in pediatric vertigo, particularly in Vestibular Migraine of Childhood (VMC), probable VMC (pVMC), Recurrent Vertigo of Childhood (RVC), and unspecified categories, by delineating clinical characteristics and prevalence to refine diagnostics and treatments.
METHODS: Retrospective analysis of 102 pediatric patients (five to 18 years; 46 females, 56 males) at the Dizziness Center of the Otolaryngology Department in a tertiary-level hospital from January 2019 to December 2023. Patients were classified into VMC, pVMC, RVC, and indeterminate groups. Evaluations included audiometry and vestibular tests (video head impulse test [vHIT] or caloric testing), conducted in the audiology unit and vestibular testing laboratory. Data were analyzed using IBM SPSS 20.0.
RESULTS: Diagnoses were 8.8% VMC, 31.4% pVMC, 51.0% RVC, and 8.8% indeterminate. Nausea and vomiting were common in VMC and pVMC; cochlear symptoms like tinnitus and hearing loss predominated in VMC. Although vestibular testing showed no significant group differences, VMC had more vHIT abnormalities and RVC had more caloric test anomalies.
CONCLUSIONS: This study highlights the need for comprehensive diagnostics in pediatric vestibular disorders, revealing unique and overlapping traits across VMC, pVMC, and RVC. Insights call for further research to refine diagnostic criteria and improve treatment methods.
While lip repositioning has been established as a treatment modality to address excess gum display (EGD) , an often overlooked contributing factor is the lack of lip support. This is often caused by the architecture of the maxilla at the subnasal area. Maxillary overgrowth may give rise to a subnasal skeletal depression producing decreased lip support and marked upper lip retraction during a smile.

Restricting muscle pull by lip repositioning surgery as a treatment option limits muscle movement, however it does not address lip support. In 2018 an alternative intervention was later proposed in a case report study . The technique involves raising a full thickness flap and applying PMMA (polymethyl methacrylate) cement to fill the subnasal depression and limit the upper lip movement. Since its introduction, a limited number of studies have attempted to investigate the technique, however there are not enough studies to support the outcome or the stability of the technique. The aim of the current study is to evaluate the use of a tunnel technique with a 3D printed PEEK (Polyetherether ketone) shell to fill the skeletal subnasal depression
FIELD: medicine, obstetrics. SUBSTANCE: the method puts forward to apply perfluorane to be intravenously injected through infusomatic device at 50 ml/h velocity at the dosage of 3.5 ml/kg body weight, 3-4 times, not more. The method in question enables to improve uterine- placental blood flow, increase saturation of intervillous space with an oxygen to enhance activity of extravillous cytotrophoblast. Selected doses and modes enable to exclude side effects caused by perfluorane in pregnant women. EFFECT: higher efficiency of therapy. 2 ex, 10 tbl
Iron has been proposed to contribute to atherogenesis in humans by facilitating the oxidation of lipoproteins. This observational study will evaluate the association between frequency of blood donation - expected to be associated with relatively reduced body iron stores in frequent donors - and carotid atherosclerosis. The primary outcome variable will be whether the presence and extent of asymptomatic carotid atherosclerosis as measured by ultrasound is greater in infrequent (less than or equal to 1 donations/year greater than or equal to 5 years) vs. frequent (greater than or equal to 4 donations/year greater than or equal to 5 years) blood donors. Body iron stores, lipid and hemostatic parameters, nitric oxide formation, inflammatory parameters, and markers of vascular oxidative stress will be analyzed as secondary outcome measures. Laboratory analysis and ultrasound testing will be performed blinded to the patient's phlebotomy and iron status. Sixty frequent (n=40 males greater than 40 y/o, n=20 females greater than 50 y/o) and 60 infrequent (n=40 males greater than 40 y/o, n=20 females greater than 50 y/o) blood donors will be recruited for this study from the Department of Transfusion Medicine, W. G. Magnuson Clinical Center. All donors will be assessed for study eligibility and cardiovascular risks during the screening visit. The presence of atherosclerotic lesions by carotid ultrasound and secondary outcome parameters will be assessed during a second visit.
CAF treatment was performed by starting with two divergent releasing incisions lateral to the recessed area. A sulcular incision was made to unite the releasing incisions and the flap was raised beyond the mucogingival junction (MGJ) in split-full-split thickness. Sling sutures were placed to stabilize the flap in a coronal position 2 mm above the CEJ, followed by interrupted sutures to close the releasing incisions. For electrical stimulation, a unit consisting of a signal generator, a power supply, and circuit board will be used. Conductive electrodes for electrical current application will be applied to the vestibular gingival surface on each side of the flap, at a distance of 3 mm from the relaxing incisions and an alternating current of 100 μA at 9 kHz, will be distributed in order to traverse the operated area. A single application of electrical stimulation will be given for 120 seconds, once a day for five days after surgery.
The present invention is a topical skin preparation for treatment of fungal infections of the skin and nails. The preparation comprises triacetin in combination with an antifungal agent. In a preferred form, the preparation further comprises, a fatty acid source such as a fish oil. In a preferred embodiment, cod liver oil and tolnaftate are used in combination with triacetin. The concentrations of these constituents are 96.0-99.0% concentration triacetin, 0.5-3.0% concentration tolnaftate and 0.5-1.0% concentration cod liver oil, in one preferred embodiment. Other compounds, such as ethyl alcohol, amino acids such as n-acetylcysteine, and herbal additives may also be added to the preparation. Further, other antifungal agents such as nystatin, clortimazole, econazole, ketoconazole, miconazole, solconazole, oxiconizole, naftifine, terbinafine, and butenafine, for example, may be substituted for the antifungal agent tolnaftate. The preparation of the present invention is effective in treating immune compromised patients and those with diabetes, as well as relatively healthy persons.
PURPOSE:To obtain a detergent and a cosmetic having softening action on human skin, comprising substances in aroma and essence to provide the skin with refreshing feeling, drying effects on wet pimple, aiming dressing of skin and hair and removal of foul breath and body smell, containing essence of ginger. CONSTITUTION:A detergent cosmetic containing a substance obtained by filtering essence of ginger or by extracting the essence with an alcohol or a diluted solution by diluting the substance with water. In the detergent cosmetic, aromatic irritation of ginger provides a refreshing feeling, eliminates stretch of the skin, make the skin wet, dries pimples especially on the breast and the back and can suppress foul breath and body smell. When the detergent cosmetic is applied to the whole body, the cosmetic has warmth keeping effects after taking a bath. When the cosmetic is used for hair on the scalp, the cosmetic suppresses itch and provides hair with moisture. When the cosmetic is added to a detergent or dentifrice, foams becomes fine and abundant, raises washing power and provides a refreshing feeling at the end of washing.
Graduate and post-graduate students were recruited in Federal University of Santa Maria to study participation. First, the health status of volunteers was analysed by questioner application (to evaluate lifestyle, family history, individual characteristics), anthropometric (height, weight, waist circumference) and biochemical parameters (glucose, lipid profile, transaminases, urea, creatinine) measurements. According to inclusion criteria, 18 volunteers were able to study participation, but just 16 people remained until the end of the study.

Each treatment was composed by 7 capsules (containing 0.05 mg carotenoid or placebo/kg b.w.) which should be consumed once a day (preferably in the morning), during 7 days. It was conducted a randomized, double blind, placebo-controlled crossover clinical trial, where 16 participants received 4 proposed treatments (bixin, norbixin, lycopene and placebo) in different periods. To plasma, serum and red blood cells (RBC) obtainment, 2 fasting blood collections were made, in the beginning (Day 0) and the end (Day 7) of each treatment. These samples were used for evaluating the ex vivo oxidation of LDL induced by copper sulphate and biochemical and oxidative biomarkers measurements.
The aim of the PEPCAD III substudy is to assess the efficacy of the DEBlue® Paclitaxel-eluting stent system in the treatment of stenoses in native coronary arteries compared to the Sirolimus-eluting Cypher stent by intravascular ultrasound (IVUS) and to study the influence of both devices on endothelial function, coronary flow reserve, and stem cell mobilization. This study is a prospective, randomized, single-center, two-armed phase-II study. During the PEPCAD III trial, 40 patients of the Homburg / Saar center will be randomly assigned to ei-ther one of the treatment groups (20 patients treated with DEBlue, 20 patients with Cypher®). Patients with stable or selected forms of unstable angina or documented ischemia due to a significant lesion in a native coronary artery will be included. Vessels may not supply an en-tirely infarcted myocardial area. Additional 20 patients receiving uncoated stents (Coroflex® Blue, B.Braun) will undergo the same diagnostic procedures.
A coating composition for medicaments (see Group VI) comprises a film-forming substance having uniformly dispersed therein a finely-divided mineral solid which is inert to the film-forming substance and which is present in amount sufficient to prevent the film from cracking and crazing upon ageing, i.e. 10-150 per cent by weight based on the weight of the film-forming substance.  The film-forming substance may be a dicarboxylic acid ester of cellulose containing free carboxyl groups such as cellulose acetate phthalate and cellulose propionate phthalate, or a cellulose ether.  Specified mineral solids include talc, fuller's earth, diatomaceous earth, calamine, bentonite, pumice and insoluble sodium metaphosphate. Plasticizers, such as propylene glycol, triacetin, tripropionin, ethyl acid adipate and butyl acid phthalate, and edible surface-active agents, such as lecithin and sorbitan monooleate, may also be present.  In an example erythromycin tablets are coated with a composition comprising cellulose acetate phthalate. talc, anhydrous alcohol, anhydrous acetone, propylene glycol and sorbitan monooleate, Specification 526,276,[Group IV], is referred to.ALSO:An enteric coating composition comprises an enteric film-forming substance having uniformly dispersed therein a finely divided mineral solid which is inert to the film-forming substance and which is present in an amount sufficient to prevent the film from cracking and crazing upon ageing, i.e. 10-150 per cent by weight based on the weight of the film-forming substance. The film-forming substance may be a dicarboxylic acid ester of cellulose containing free carboxyl groups such as cellulose acetate phthalate and cellulose propionate phthalate, polyvinyl acetate, polyvinylphthalate, a cellulose ether, a copolymer of an aliphatic dibasic unsaturated acid and a vinyl compound, shellac, zein, balsam tolu or a higher fatty acid. Specified mineral solids include talc, fuller's earth, diatomaceous earth, calamine, bentonite, pumice and insoluble sodium metaphosphate. Plasticizers, such as propylene glycol, triacetin, tripropionin, ethyl acid adipate and butyl acid phthalate and edible surface active agents such as lecithin and sorbitan monooleate may also be present.  Medicaments which may be coated include antibiotics such as erythromycin, ammonium chloride, sodium salicylate, diethylstilboestrol, gentian violet, barbiturates; anti-epileptics, acriflavine and ferrous sulphate.  These materials may be coated by known methods.  In an example erythromycin tablets are coated with a composition comprising cellulose acetate phthalate, talc, anhydrous alcohol anhydrous acetone, propylene glycol and sorbitan mono-oleate. Specification 526,276 is referred to.
In an ongoing feasibility study (HYBOBI), brain-injured subjects are exposed to hyperbaric oxygen at 1.5 atmospheres for 60 minutes. They receive this exposure five days per week, and receive 60 total sessions. Prior to hyperbaric oxygen, these study subjects have neurologic, cognitive, and functional measures. The measures are repeated at the conclusion of 60 hyperbaric oxygen sessions, and again six months later. The goal of the HYBOBI feasibility study is to learn about these patients and determine possible hyperbaric oxygen effects, if any, to prepare for a blinded randomized controlled clinical trial.

This study adds an imaging component to the HYBOBI study, further investigating brain changes in participants. Participants will undergo Brain MRI (Magnetic Resonance Imaging) using a 3 tesla magnet, and Brain CT (Computed Tomography) Angiogram. Subjects will undergo imaging before receiving hyperbaric oxygen and within 2 weeks of completion of the 60 hyperbaric sessions.
Laughter yoga for nurses The experimental group was divided into three groups as 18-17-16 people. Sessions 1st group Monday-Thursday between 12:00-13:00; 2nd group Tuesday-Friday between 17:00-18:00; The third group was held on Wednesday Saturday between 20:00-21:00.laughter yoga for nurses-Deep breathing exercises Deep breathing exercises (5 minutes), Warm-up exercises (10 minutes) laughter yoga for nurses-Childish games Childish games (10 minutes), Laughter exercises (15 minutes).
Effective pain management is crucial for modified radical mastectomy (MRM) surgeries. The Serratus Posterior Superior Intercostal Plane Block (SPSIPB), introduced in 2023, shows promise for postoperative analgesia. This study was designed to demonstrate the analgesic efficacy of the SPSIPB in MRM surgeries. SPSIPB was administered to 7 patients who underwent MRM for postoperative analgesia. NRS scores of patients were ≤4 and total tramadol consumption was 0 mg in 3 of 7 patients. In conclusion, SPSIPB appears to be an effective, safe, and easily applicable option for analgesia.
The invention discloses a yam rhizome protein pill, belonging to the technical field of Chinese Pharmacopoeia. The treating effect is achieved by utilizing special compositions and attributes of traditional Chinese medicines and taking a finished medicament. The yam rhizome protein pill is used for treating urine chyluria according to a secret recipe handed down in the family, has good treatment effect to a urine protein through large clinical verification with the cure rate of above 85 percent. The yam rhizome protein pill has reasonable collocation based on a traditional Chinese medicine formula, stimulates the menstrual flow to achieve tissue coordination as well as eliminates pathogen and supports the healthy energy to enable proteinuria not to relapse after curing. In the yam rhizome protein pill, salt yam rhizome is taken as a main medicine to remove damp and turbid; spicebush, aconite and cinnamon are taken as auxiliary medicines to warm a kidney; grass leaved sweetflag is taken as an adjuvant to promote restoration consciousness, facilitate the urine, warm the kidney and eliminate dampness; ginseng and astragalus are taken as conductant medicines to replenish qi and invigorate a spleen; and pokeweed is added to excite a renal vessel motor center and eliminate stasis and invigorate the kidney. The yam rhizome protein pill fulfills the treating functions of eliminating the urine protein and strengthening a viscera such as the kidney, a liver, the spleen and the like, thereby achieving the treatment effect.
Subjects will receive GSK1278863 once daily orally at a starting dose of 4 milligrams (mg) on Day 1, and continued until the day of Week 4. From Weeks 4 to 24, interruption of treatment or dose adjustments will be made within the maintenance dose range of 1 mg to 24 mg according to the dose adjustment algorithm to achieve and/or maintain Hgb within the target range (10.0 to 12.0 g/dL) based on the Hgb value measured every 4 weeks. Dose changes will be made every 4 weeks. Iron replacement therapy will be given according to the standard starting criteria.
The current German newborn screening (NBS) panel includes 13 inherited metabolic diseases (IMDs). In addition, a NBS pilot study in Southwest Germany identifies individuals with propionic acidemia (PA), methylmalonic acidemia (MMA), combined and isolated remethylation disorders (e.g., cobalamin [cbl] C and methylenetetrahydrofolate reductase [MTHFR] deficiency), cystathionine β-synthase (CBS) deficiency, and neonatal cbl deficiency through one multiple-tier algorithm. The long-term health benefits of screened individuals are evaluated in a multicenter observational study. Twenty seven screened individuals with IMDs (PA [N = 13], MMA [N = 6], cblC deficiency [N = 5], MTHFR deficiency [N = 2] and CBS deficiency [N = 1]), and 42 with neonatal cbl deficiency were followed for a median of 3.6 years. Seventeen screened IMD patients (63%) experienced at least one metabolic decompensation, 14 of them neonatally and six even before the NBS report (PA, cbl-nonresponsive MMA). Three PA patients died despite NBS and immediate treatment. Fifteen individuals (79%) with PA or MMA and all with cblC deficiency developed permanent, mostly neurological symptoms, while individuals with MTHFR, CBS, and neonatal cbl deficiency had a favorable clinical outcome. Utilizing a combined multiple-tier algorithm, we demonstrate that NBS and specialized metabolic care result in substantial benefits for individuals with MTHFR deficiency, CBS deficiency, neonatal cbl deficiency, and to some extent, cbl-responsive MMA and cblC deficiency. However, its advantage is less evident for individuals with PA and cbl-nonresponsive MMA. SYNOPSIS: Early detection through newborn screening and subsequent specialized metabolic care improve clinical outcomes and survival in individuals with MTHFR deficiency and cystathionine-β-synthase deficiency, and to some extent in cobalamin-responsive methylmalonic acidemia (MMA) and cblC deficiency while the benefit for individuals with propionic acidemia and cobalamin-nonresponsive MMA is less evident due to the high (neonatal) decompensation rate, mortality, and long-term complications.
Seventy-eight obese subjects aged 36 ± 1 years and BMI of 33 ± 3 kg were randomly divided into two parallel groups: (1) orange juice (n = 39), composed of individuals subjected to a diet low caloric diet and plus intake of 500 ml orange juice; (2) control (n = 39) composed of individuals subjected to a diet low in calories. The recruitment process began in September 2015, the intervention was carried out from October 2015 to January 2016, and the data analysis started in February 2016. The sample number took into account variances on body weight with a type I error α = 0.05 and a type II error β = 0.2 (80% power). The minimum sample size should have 36 individuals per group (n = 72), considering an approximately 15% dropout rate. Thus, the final sample size of study was constituted by 39 individuals per group (n = 78). Primary and secondary endpoints were the reduction of weight and modification of the levels of obesity-related metabolic biomarkers, respectively. Normality and homogeneity of data were tested. T-test was conducted to identify possible differences between OJ and control groups at baseline. A linear mixed-effects model was apply to determine the time effect within and between groups (post hoc), and P significance was set up ≤ 0.05. The assessment of body composition, metabolic biomarkers and food intake were analyzed over a 12-week intervention.
Fifty (50) age and sex matched euthyroid subjects will serve as the control group. Control euthyroid subjects will be evaluated once at baseline and after 12 weeks.
Vemurafenib 960 mg by mouth two times a day 2 weeks post-surgery, or if patients have not sufficiently recovered at that point, as soon as their condition permits. Patients in Group A restaged 8 weeks after resuming drug. If patients in Group A demonstrate either stable or regressing disease, they will continue on vemurafenib with restaging occurring every 8 weeks until no longer benefitting from the drug.
FIELD: pharmacy. SUBSTANCE: composition has pharmaceutically effective amount of medicinal or diagnostic agent and the following components, mas. /vol. %: methylcellulose containing methoxyl-groups at the range 26-33%, 0.2-2.1; citric acid, 1.2-2.3; polyethylene glycol (average molecular mass is 300-50000 Da), 0.5-13; and pharmaceutically acceptable agent for pH value control. Composition has pH from 3 to 10. Composition is a liquid before administration and forms gel at body temperature immediately after administration or use. Composition provides bioavailability of pharmaceutically effective component and maintains effect of medicinal agents for the long period. Composition can be used in ophthalmology, dermatology and for body cavity treatment. EFFECT: enhanced effectiveness of composition. 12 cl, 2 dwg, 4 tbl